title: Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris.
abstract: BACKGROUND
  New topical treatments for acne vulgaris are needed for patients who have tolerance problems with current treatments.
  
  
  OBJECTIVE
  To compare the efficacy and tolerance of a lipophillic derivative of salicylic acid (lipo hydroxy acid or LHA) containing formulation and 5% benzoyl peroxide in subjects with acne vulgaris.
  
  
  METHODS
  Eighty subjects with mild to moderate facial acne were randomized to receive either the LHA formulation twice a day or benzoyl peroxide once a day for 12 weeks. Efficacy and tolerance were evaluated at days 0, 28, 56 and 87. Results LHA formulation and benzoyl peroxide decreased the number of inflammatory lesions from baseline to week 12 by 44% and 47% and noninflammatory lesions by 19% and 23%, respectively. There was no statistically significant difference between the two treatments (P = 0.748; P = 0.445).
  
  
  CONCLUSIONS
  These results suggest that the LHA formulation could be a treatment option to consider in mild to moderate acne vulgaris patients that are intolerant to benzoyl peroxide.
authors.affiliation: Innovaderm Research, Montreal, Canada. rbissonnette@innovaderm.ca
authors.forename: R
authors.initials: R
authors.lastname: Bissonnette
authors.forename: C
authors.initials: C
authors.lastname: Bolduc
authors.forename: S
authors.initials: S
authors.lastname: Seité
authors.forename: S
authors.initials: S
authors.lastname: Nigen
authors.forename: N
authors.initials: N
authors.lastname: Provost
authors.forename: C
authors.initials: C
authors.lastname: Maari
authors.forename: A
authors.initials: A
authors.lastname: Rougier
mesh_terms: D000152:Acne Vulgaris / Q000175:diagnosis / Q000188:drug therapy*; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001585:Benzoyl Peroxide / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D006880:Hydroxy Acids / Q000627:therapeutic use*; D020714:Maximum Tolerated Dose; D011336:Probability; D018570:Risk Assessment; D020156:Salicylic Acid; D012720:Severity of Illness Index; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006880:Hydroxy Acids; D020156:Salicylic Acid; D001585:Benzoyl Peroxide